Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Yaning Wang, PhD
Advertisement
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
Articles by Yaning Wang, PhD
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Advertisement
Latest Updated Articles
PK in Late Phase TrialsPublished: February 1st 2012 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results
4
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
